+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Depression - Pipeline Review, H2 2019

  • ID: 4866554
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 595 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adamed Sp zoo
  • Bristol-Myers Squibb Co
  • Evotec SE
  • KemPharm Inc
  • NeuroRx Inc
  • Relmada Therapeutics Inc
  • MORE
Depression - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H2 2019, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 15, 37, 37, 3, 85, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 13 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adamed Sp zoo
  • Bristol-Myers Squibb Co
  • Evotec SE
  • KemPharm Inc
  • NeuroRx Inc
  • Relmada Therapeutics Inc
  • MORE
Introduction
Depression - Overview
Depression - Therapeutics Development
Depression - Therapeutics Assessment
Depression - Companies Involved in Therapeutics Development
Depression - Drug Profiles
Depression - Dormant Projects
Depression - Discontinued Products
Depression - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Depression, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 9: Number of Products under Development by Universities/Institutes, H2 2019
Table 10: Products under Development by Companies, H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 15: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 16: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 17: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 18: Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Table 19: Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Table 20: Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Table 21: Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Table 22: Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Table 23: Products under Development by Universities/Institutes, H2 2019
Table 24: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 25: Number of Products by Stage and Target, H2 2019
Table 26: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 27: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 28: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Table 29: Number of Products by Stage and Mechanism of Action, H2 2019
Table 30: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 31: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 32: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 33: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Table 34: Number of Products by Stage and Route of Administration, H2 2019
Table 35: Number of Products by Stage and Molecule Type, H2 2019
Table 36: Depression - Pipeline by Acadia Pharmaceuticals Inc, H2 2019
Table 37: Depression - Pipeline by Adamed Sp zoo, H2 2019
Table 38: Depression - Pipeline by Addex Therapeutics Ltd, H2 2019
Table 39: Depression - Pipeline by Aequus Pharmaceuticals Inc, H2 2019
Table 40: Depression - Pipeline by Aision Biotechnologies Inc, H2 2019
Table 41: Depression - Pipeline by Alkermes Plc, H2 2019
Table 42: Depression - Pipeline by Allergan Plc, H2 2019
Table 43: Depression - Pipeline by Amorsa Therapeutics Inc, H2 2019
Table 44: Depression - Pipeline by Anavex Life Sciences Corp, H2 2019
Table 45: Depression - Pipeline by Angelini Group, H2 2019
Table 46: Depression - Pipeline by Antheia Inc, H2 2019
Table 47: Depression - Pipeline by Asulon Therapeutics Inc, H2 2019
Table 48: Depression - Pipeline by Atai Life Sciences AG, H2 2019
Table 49: Depression - Pipeline by Avanir Pharmaceuticals Inc, H2 2019
Table 50: Depression - Pipeline by Avicanna Inc, H2 2019
Table 51: Depression - Pipeline by Axsome Therapeutics Inc, H2 2019
Table 52: Depression - Pipeline by Azevan Pharmaceuticals Inc, H2 2019
Table 53: Depression - Pipeline by Beloteca Inc, H2 2019
Table 54: Depression - Pipeline by Bionomics Ltd, H2 2019
Table 55: Depression - Pipeline by BioStem Technologies Inc, H2 2019
Table 56: Depression - Pipeline by BioXcel Therapeutics Inc, H2 2019
Table 57: Depression - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 58: Depression - Pipeline by Bristol-Myers Squibb Co, H2 2019
Table 59: Depression - Pipeline by Calico LLC, H2 2019
Table 60: Depression - Pipeline by Celgene Corp, H2 2019

List of Figures
Figure 1: Number of Products under Development for Depression, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Acadia Pharmaceuticals Inc
  • Adamed Sp zoo
  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc
  • Aision Biotechnologies Inc
  • Alkermes Plc
  • Allergan Plc
  • Amorsa Therapeutics Inc
  • Anavex Life Sciences Corp
  • Angelini Group
  • Antheia Inc
  • Asulon Therapeutics Inc
  • Atai Life Sciences AG
  • Avanir Pharmaceuticals Inc
  • Avicanna Inc
  • Axsome Therapeutics Inc
  • Azevan Pharmaceuticals Inc
  • Beloteca Inc
  • Bionomics Ltd
  • BioStem Technologies Inc
  • BioXcel Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Calico LLC
  • Celgene Corp
  • Cellix Bio Pvt Ltd
  • Celon Pharma SA
  • Cerecor Inc
  • CGeneTech (Suzhou China) Co Ltd
  • Chase Therapeutics Corp
  • Clera Inc
  • Clexio Biosciences Ltd
  • Compass Pathways Ltd
  • CSPC Pharmaceutical Group Ltd
  • CuroNZ Ltd
  • Delpor Inc
  • Denovo Biopharma LLC
  • Douglas Pharmaceuticals Ltd
  • Dracen Pharmaceuticals Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Evecxia Inc
  • Evotec SE
  • Fabre-Kramer Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • GliaCure Inc
  • GNT Pharma Co Ltd
  • Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
  • H. Lundbeck AS
  • HEC Pharm Co Ltd
  • HolsboerMaschmeyer NeuroChemie GmbH
  • Hua Medicine Shanghai Ltd
  • Iltoo Pharma
  • Impel NeuroPharma Inc
  • Initiator Pharma AS
  • Intas Pharmaceuticals Ltd
  • IntelGenx Corp
  • Intra-Cellular Therapies Inc
  • INVENT Pharmaceuticals Inc
  • iX Biopharma Ltd
  • Jiangsu Gibel Pharmaceutical Co Ltd
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • Jina Pharmaceuticals Inc
  • Johnson & Johnson
  • Kamat Pharmatech LLC
  • KemPharm Inc
  • Kissei Pharmaceutical Co Ltd
  • Krenitsky Pharmaceuticals Inc
  • Kures Inc
  • Lactocore
  • Lead Discovery Center GmbH
  • Les Laboratoires Servier SAS
  • Lixte Biotechnology Holdings Inc
  • Luye Pharma Group Ltd
  • Lyndra Inc
  • Mapi Pharma Ltd
  • Mapreg SAS
  • Marinus Pharmaceuticals Inc
  • MedinCell SA
  • Medlab Clinical Ltd
  • MElkin Pharmaceuticals
  • Mental-Heal Ltd
  • Meta-IQ ApS
  • Methylation Sciences Inc
  • miCure Therapeutics Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Navitor Pharmaceuticals Inc
  • Neurocrine Biosciences Inc
  • Neurocyte Therapeutics Inc
  • Neurolixis Inc
  • NeuroNascent Inc
  • NeuroRx Inc
  • Neurotrope Bioscience Inc
  • Nippon Chemiphar Co Ltd
  • Novartis AG
  • Nubiyota LLC
  • Omeros Corp
  • Orbis Biosciences Inc
  • Orexigen Therapeutics Inc
  • Otsuka Holdings Co Ltd
  • Overseas Pharmaceuticals Ltd
  • Pfizer Inc
  • PharmaMax Corp
  • Pharmnovo AB
  • PharmoRx Therapeutics Inc
  • Phenoquest AG
  • Phytecs
  • PNB Vesper Life Science Pvt Ltd
  • Praxis Precision Medicines Australia Pty Ltd
  • Primetime Life Sciences LLC
  • Protagenic Therapeutics Inc
  • Prous Institute for Biomedical Research SA
  • Psy Therapeutics Inc
  • Relmada Therapeutics Inc
  • Repurposed Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Sage Therapeutics Inc
  • Saniona AB
  • Seelos Therapeutics, Inc.
  • Seneca Biopharma Inc
  • Shanghai SIMR Biotech Co Ltd
  • Shanghai Synergy Pharmaceutical Sciences Co Ltd
  • Shenox Pharmaceuticals LLC
  • Siragen Pharmaceuticals Inc
  • SK Biopharmaceuticals Co Ltd
  • Small Pharma Ltd
  • Sosei Heptares
  • Sound Pharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Sunovion Pharmaceuticals Inc
  • Supernus Pharmaceuticals Inc
  • Suven Life Sciences Ltd
  • SyneuRx International Corp
  • Syntropharma Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Techfields Pharma Co Ltd
  • Terran Biosciences Inc
  • Trevena Inc
  • VistaGen Therapeutics Inc
  • WhanIn Pharmaceutical Co Ltd
  • XW Laboratories Inc
  • Yantai YenePharma Co Ltd
  • Yungjin Pharm Co Ltd
  • Zhejiang Jinhua Conba Bio-pharm Co Ltd
  • Zysis Ltd
Note: Product cover images may vary from those shown
Adroll
adroll